Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):380–386. doi: 10.1128/aac.40.2.380

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.

S Balakrishna Pai 1, S H Liu 1, Y L Zhu 1, C K Chu 1, Y C Cheng 1
PMCID: PMC163120  PMID: 8834884

Abstract

2'-Fluoro-5-methyl-beta-L-arabinofuranosyl uracil (L-FMAU) was discovered to have potent antiviral activity against hepatitis B virus (HBV). L-FMAU was more potent than its D-enantiomer and produced dose-dependent inhibition of the viral DNA replication in 2.2.15 cells (human HepG2 cells with the HBV genome), with a 50% inhibitory concentration of 0.1 microM. There was no inhibitory effect on HBV transcription or protein synthesis. In the 2.2.15 cell system, L-FMAU did not show any toxicity up to 200 microM, whereas the D-enantiomer was toxic, with a 50% inhibitory concentration of 50 microM. Repeated treatments of HepG2 cells with L-FMAU at a 1 microM concentration for 9 days did not result in any decrease in the total mitochondrial DNA content, suggesting that a mode of toxicity similar to that produced by 2',3'-dideoxycytidine is unlikely. Also at concentrations as high as 200 microM, L-FMAU did not adversely affect mitochondrial function as determined by lactic acid production by L-FMAU-treated hepatoma cells. L-FMAU was metabolized in the cells to its mono-, di-, and triphosphates, A dose-dependent inhibition of HBV DNA synthesis by L-FMAU triphosphate was observed in the DNA polymerase assays with isolated HBV particles, suggesting that the mode of action of this compound could involve viral polymerase. However, L-FMAU was not incorporated into the cellular DNA. Considering the potent inhibition of the viral DNA synthesis and the nontoxicity of L-FMAU towards the host DNA synthetic machinery, this compound should be further explored for development as asn anti-HBV drug.

Full Text

The Full Text of this article is available as a PDF (357.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  2. Chang C. N., Doong S. L., Zhou J. H., Beach J. W., Jeong L. S., Chu C. K., Tsai C. H., Cheng Y. C., Liotta D., Schinazi R. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem. 1992 Jul 15;267(20):13938–13942. [PubMed] [Google Scholar]
  3. Chang C. N., Skalski V., Zhou J. H., Cheng Y. C. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992 Nov 5;267(31):22414–22420. [PubMed] [Google Scholar]
  4. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  5. Cheng Y. C., Grill S. P., Dutschman G. E., Nakayama K., Bastow K. F. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem. 1983 Oct 25;258(20):12460–12464. [PubMed] [Google Scholar]
  6. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  7. Chu C. K., Ma T., Shanmuganathan K., Wang C., Xiang Y., Pai S. B., Yao G. Q., Sommadossi J. P., Cheng Y. C. Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother. 1995 Apr;39(4):979–981. doi: 10.1128/aac.39.4.979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Colacino J. M., Malcolm S. K., Jaskunas S. R. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother. 1994 Sep;38(9):1997–2002. doi: 10.1128/aac.38.9.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cui L., Yoon S., Schinazi R. F., Sommadossi J. P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest. 1995 Feb;95(2):555–563. doi: 10.1172/JCI117698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Di Bisceglie A. M., Rustgi V. K., Hoofnagle J. H., Dusheiko G. M., Lotze M. T. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988 Mar;108(3):390–401. doi: 10.7326/0003-4819-108-3-390. [DOI] [PubMed] [Google Scholar]
  11. Doong S. L., Tsai C. H., Schinazi R. F., Liotta D. C., Cheng Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8495–8499. doi: 10.1073/pnas.88.19.8495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gosselin G., Schinazi R. F., Sommadossi J. P., Mathé C., Bergogne M. C., Aubertin A. M., Kirn A., Imbach J. L. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother. 1994 Jun;38(6):1292–1297. doi: 10.1128/aac.38.6.1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kamali F. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues. Clin Investig. 1993 May;71(5):392–405. doi: 10.1007/BF00186630. [DOI] [PubMed] [Google Scholar]
  14. Larder B. A., Chesebro B., Richman D. D. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990 Mar;34(3):436–441. doi: 10.1128/aac.34.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lewis W., Meyer R. R., Simpson J. F., Colacino J. M., Perrino F. W. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate. Biochemistry. 1994 Dec 6;33(48):14620–14624. doi: 10.1021/bi00252a030. [DOI] [PubMed] [Google Scholar]
  16. Lin T. S., Luo M. Z., Liu M. C., Pai S. B., Dutschman G. E., Cheng Y. C. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol. 1994 Jan 20;47(2):171–174. doi: 10.1016/0006-2952(94)90002-7. [DOI] [PubMed] [Google Scholar]
  17. Lin T. S., Luo M. Z., Liu M. C., Pai S. B., Dutschman G. E., Cheng Y. C. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J Med Chem. 1994 Mar 18;37(6):798–803. doi: 10.1021/jm00032a013. [DOI] [PubMed] [Google Scholar]
  18. Matthes E., Langen P., von Janta-Lipinski M., Will H., Schröder H. C., Merz H., Weiler B. E., Müller W. E. Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother. 1990 Oct;34(10):1986–1990. doi: 10.1128/aac.34.10.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Matthes E., Reimer K., von Janta-Lipinski M., Meisel H., Lehmann C. Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs. Antimicrob Agents Chemother. 1991 Jun;35(6):1254–1257. doi: 10.1128/aac.35.6.1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Meisel H., Reimer K., von Janta-Lipinski M., Bärwolff D., Matthes E. Inhibition of hepatitis B virus DNA polymerase by 3'-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs. J Med Virol. 1990 Feb;30(2):137–141. doi: 10.1002/jmv.1890300211. [DOI] [PubMed] [Google Scholar]
  21. Price P. M., Banerjee R., Acs G. Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8541–8544. doi: 10.1073/pnas.86.21.8541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ruth J. L., Cheng Y. C. Nucleoside analogues with clinical potential in antivirus chemotherapy. The effect of several thymidine and 2'-deoxycytidine analogue 5'-triphosphates on purified human (alpha, beta) and herpes simplex virus (types 1, 2) DNA polymerases. Mol Pharmacol. 1981 Sep;20(2):415–422. [PubMed] [Google Scholar]
  23. Sachs M. K. Antiretroviral chemotherapy of human immunodeficiency virus infections other than with azidothymidine. Arch Intern Med. 1992 Mar;152(3):485–501. [PubMed] [Google Scholar]
  24. Schinazi R. F., Gosselin G., Faraj A., Korba B. E., Liotta D. C., Chu C. K., Mathé C., Imbach J. L., Sommadossi J. P. Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother. 1994 Sep;38(9):2172–2174. doi: 10.1128/aac.38.9.2172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sells M. A., Chen M. L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005–1009. doi: 10.1073/pnas.84.4.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yarchoan R., Pluda J. M., Perno C. F., Mitsuya H., Thomas R. V., Wyvill K. M., Broder S. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci. 1990;616:328–343. doi: 10.1111/j.1749-6632.1990.tb17853.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES